Results 251 to 260 of about 20,827,425 (307)
TRUE-MOGAD Score: A Novel Scoring System to Identify MOGAD Among Positive MOG-IgG Test Results. [PDF]
Neurol Neuroimmunol NeuroinflammVilaseca A, Filippatou AG, Said Y, Sechi E, Syc-Mazurek SB, Cacciaguerra L, Guo K, Vorasoot N, Niederschweiberer M, Thakolwiboon S, Sagen JA, Lopez-Chiriboga SA, Tillema JM, Chen JJ, Pittock SJ, Sotirchos ES, Flanagan EP. +16 moreeuropepmc +1 more sourceContent
Haruyo Yasui, Yasushi Sakata, Ryo Kawasaki, Ken-Ichi Hirata, Yusuke Tomoi, Mitsuyoshi Takahara, Yoshimitsu Soga, Taichi Hirano, Kazuki Tsunoda, Tomonori Katsuki, Kenji Ando, Yasutaka Yamauchi, Osamu Iida, Masahiko Fujihara, Daizo Kawasaki, Kazunori Horie, Amane Kozuki, Tatsuro Takei, Kenji Ogata, Kensaku Nishihira, Keiichiro Komiya, Kensho Baba, Yasuhiro Honda, Keisuke Yamamoto, Kosuke Kadooka, Toshiyuki Kimura, Takeaki Kudo, Keiichi Ashikaga, Yoshisato Shibata, Kenichi Tsujita, Naoki Yoshioka, Takahiro Tokuda, Akiko Tanaka, Shunsuke Kojima, Kohei Yamaguchi, Takashi Yanagiuchi, Yasuhiro Morita, Tatsuya Nakama, Itsuro Morishima, Tomoaki Kudo, Toru Kuratani, Yoshiki Sawa, Shigeru Miyagawa +42 moreopenalex +2 more sourcesEngineered extracellular vesicles enriched with the miR‐214/199a cluster enhance the efficacy of chemotherapy in ovarian cancer
Molecular Oncology, EarlyView.Loss of the miR‐214/199a cluster is associated with recurrence in ovarian cancer. Engineered small extracellular vesicles (m214‐sEVs) elevate miR‐214‐3p/miR‐199a‐5p in tumor cells, suppress β‐catenin, TLR4, and YKT6 signaling, reprogram tumor‐derived sEV cargo, reduce chemoresistance and migration, and enhance carboplatin efficacy and survival in ...Weida Wang, Ayesha Alvero, Yi Qin, Mingjin Wang, Alexandra Fox, Yanfeng Li, Michael Millman, Amy Kemper, Gil Mor, Xian Shuang Liu, Michael Chopp, Zheng Gang Zhang, Yi Zhang +12 morewiley +1 more sourceInterrogating the immune landscape of microsatellite stable RAS‐mutated colon cancer
Molecular Oncology, EarlyView.COLOSSUS project RAS‐mutated MSS colon cancer study explored transcriptomics and immune cell density by immunohistochemistry (IHC), Immunoscore (IS), ISIC/TuLIS scores, mutation counts, and detected different prevalences but similar microenvironment composition across immune markers with clinical relevance for future immunotherapy combination ...Rodrigo Dienstmann, Eduardo García‐Galea, Alice O'Farrell, Zak Kinsella, Maxime Meylan, Florent Petitprez, Ingrid Arijs, Tom Venken, Hari Ps, Adrian Lärkeryd, Ian Miller, Janick Selves, Nadja Meindl‐Beinker, Fiorella Ruiz‐Pace, Elena Élez, Raquel Comas‐Navarro, Frank Lincoln, Dirk Fey, Gift Nyamundanda, Aoife Nolan, Joern Lewin, Raquel Perez‐Lopez, Jonathan Briody, Kathleen Bennett, Walter Kolch, David Matallanas, Alexander Kel, Enrique Arenas, Joaquín Arribas, Bart Ghesquière, Josep Tabernero, Julie Meilleroux, Deborah McNamara, Ray McDermott, Marvin Lim, Mary O'Reilly, Brian Bird, Lisa Stack, Lucia Moloney, Patrick Morris, Keith Egan, Maciej Milewski, Lars Scheuer, Joachim Behringer, Georg Bolz, Ramon Salazar, Cristina Santos, Andrea Ruiz, Orla Casey, Verena Murphy, Matthias Ebert, Livio Trusolino, Diether Lambrechts, Anguraj Sadanandam, Catherine Sautès‐Fridman, Jochen Prehn, Paolo Nuciforo, Jacques Fieschi, Florence Monville, Darran O'Connor, Wolf Fridman, Annette Byrne +61 morewiley +1 more sourceIMPDH inhibition enhances cytarabine efficacy in SAMHD1‐expressing leukaemia cells via guanine nucleotide depletion
Molecular Oncology, EarlyView.Cytarabine is a key therapy for acute myeloid leukaemia (AML), but its efficacy is limited by the dNTPase SAMHD1, which hydrolyses its active metabolite. Screening nucleotide biosynthesis inhibitors revealed that IMPDH inhibitors selectively sensitise SAMHD1‐proficient AML cells to cytarabine.Miriam Yagüe‐Capilla, Christopher Dirks, Caroline Eiden, Sonja K. Fesenmayer, Femke M. Hormann, Yolande Klootsema, Ingrid Lilienthal, Si Min Zhang, Nikolas Herold, Sean G. Rudd +9 morewiley +1 more source
